Nu-Med Plus Inc 的盈利品質評分為 B/38.91154。該評分基於盈利能力、增長、現金生成與資本分配以及槓桿四個維度。
Nu-Med Plus Inc 何時發布財報?
Nu-Med Plus Inc 的下一份財報預計在 2026-07-14 發布
Nu-Med Plus Inc 的預期收益是多少?
根據華爾街分析師的預測,Nu-Med Plus Inc 的預期收益為 $
Nu-Med Plus Inc 是否超出收益預期?
Nu-Med Plus Inc 最近的收益為 $, 預期。
關鍵數據
前收市價
$0.0152
開盤價
$0.0102
當日範圍
$0.0102 - $0.0102
52週區間
$0.0097 - $0.06
交易量
700
平均成交量
23.0K
股息收益率
--
每股盈餘 (TTM)
-0.00
市值
$852.2K
什麼是 NUMD?
Nu-Med Plus, Inc. engages in the design, development, and marketing of technologies utilizing nitric oxide in the medical device field. The company is headquartered in Salt Lake City, Utah and currently employs 2 full-time employees. The company went IPO on 2013-08-02. The company focuses on the creation of a nitric oxide (NO) generating formulation, a hospital bedside NO delivery system, a clinical unit for use in medical clinics and rehabilitation centers and a mobile rechargeable device to deliver nitric oxide gas to offer solutions to hospitals, health systems and the medical community throughout the world. Hospital NO Unit delivers a continuous intra-breath concentration of therapeutic NO to patients who are on a ventilator in a hospital setting. The Clinical Delivery System is a simplified version of the hospital unit. Portable Delivery System delivers NO to the patient at prescribed intervals for 24 hours per day at controlled doses by means of a nasal cannula or a face mask. Reagent Delivery offers a range of concentrations and flow rates of NO.